Trial Profile
A study evaluating the effect of food, gender, and age on the pharmacokinetics of SUVN-502.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2019
Price :
$35
*
At a glance
- Drugs Masupirdine (Primary)
- Indications Alzheimer's disease; Dementia; Schizophrenia
- Focus Pharmacokinetics
- Acronyms US IND study
- 02 Feb 2018 New trial record
- 29 Jan 2018 Results published in the Clinical Drug Investigation